In the claims:

Please <u>amend claims 6 and 7</u> by replacing them with the following rewritten versions:

6 (Amended). A substance according to claim 1 wherein the substance additionally comprises an antigen or an antigenic determinant.

7 (Amended). A pharmaceutical composition comprising the substance according to claim 1, admixed with one or more pharmaceutically acceptable carrier(s), diluent(s) or excipient(s).

Please cancel claims 2 to 5 and 8 to 11 without prejudice, and add the following new claims 12 to 28:

12. A composition according to claim 7 which is used to treat or prevent autoimmune disease, human T cell lenkaemia, transplant rejection or graft-versus-host disease, allergies, or infectious disease.


13. A peptide selected from the group consisting of SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, mixtures thereof, and homologues, variants and derivatives of any of these, which exhibit activity the same or similar to EtxB or Ctx B, but wherein the peptide does not exhibit GM-1 binding activity.

14. A peptide according to claim 13 which comprises from about 5 to about 40 amino acids.

15. A peptide according to claim 13 which is SEQ ID NO 2 or a variant thereof exhibiting 75% sequence homology to SEQ ID NO 2.

16. A peptide according to claim 13 which is SEQ ID NO 3 or a variant thereof exhibiting 75% sequence homology to SEQ ID NO 2.

D



- 18. A peptide according to claim 13 which is SEQ ID NO 5 or a variant thereof exhibiting 75% sequence homology to SEQ ID NO 2.
- 19. A composition comprising a peptide according to claim 13 and an antigen or an antigenic determinant.
- 20. A composition comprising a peptide according to claim 13 and an agent that binds specifically to the $\beta 4-\alpha 2$ loop of EtxB of CtxB.
- 21. A composition according to claim 20 wherein the agent is an antibody.
- 22. A method for treating a subject having diarrhoea comprising administering to the subject an effective amount of a composition according to claim 20.
- 23. A method of treating a subject having a disease associated with an immune disorder comprising administering to the subject an effective amount of a peptide according to claim 13.
- 24. A method for treating a subject having diarrhoea comprising administering to the subject an effective amount of a peptide according to claim 13.
- 25. A method according to claim 24 wherein the diarrhoea is cholera or an enterotoxin-mediated diarrhoeal disease.
- 26. A method for treating a subject having a toxin-mediated disorder comprising administering to the subject an effective amount of a peptide according to claim 13.
- 27. A peptide which is an isolated fragment of the β 4- α 2 loop of EtxB/CtxB and comprises the sequence shown in SEQ ID NO 2 or a sequence exhibiting 85% homology to SEQ ID NO 2.